RADAR-CNS:
Remote Assessment of Disease and Relapse – Central Nervous System

Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS) is a major new research program which studies the fluctuation of the chronic diseases of **depression**, **Multiple Sclerosis** and **epilepsy**, using remote monitoring technology (smartphone technology and wearable devices), to provide a foundation for developing a novel paradigm based on prediction and pre-emption.

RADAR-CNS is jointly led by **King's College London** and **Janssen Pharmaceutica NV**, funded by the **Innovative Medicines Initiative (IMI)**; a Public Private Partnership established between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union. It brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.

The CIBER is one of the 23 organizations from across Europe and the US that participate in the Project, through its areas of Mental Health (CIBERSAM, **Dr. Josep María Haro**) and Bioenginering, Biomaterials and Nanomedicine (CIBER-BBN, **Prof. Jordi Aguiló**).

Duration: 5 years (April 2016- March 2021)
EC contribution: 11.000.000 €
EFPIA contribution: 13.322.379 €

Partners

1. King's College London– *Institute of Psychiatry*, UK
2. Provincia Lombardo-Veneta–Ordine Ospedaliero di San Giovanni di Dio—Fatebenefratelli– *Psychiatric Epidemiology and Evaluation Unit*, Italy
3. Lygature, Netherlands
4. Università Vita-Salute San Raffaele – *Clinical Neurophysiology Department,* Italy
5. Fundacio Hospital Universitari Vall D'Hebron – Institut de Recerca– *Neurology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Spain*
6. University of Nottingham– *Division of Psychiatry & Applied Psychology, UK*
7. Centro de Investigacion Biomedica en Red (CIBER), Spain
8. Software AG, Germany
9. Region Hovedstaden– *Department of Neurology*, Denmark
10. Stichting VU-Vumc– *Psychiatry*, Netherlands
11. University Hospital, Freiburg– *Department Presurgical Epilepsy Diagnostics, Neurocenter,* Germany
12. Stichting IMEC Nederland– *WATS,* Netherlands
13. Katholieke Universiteit Leuven, Belgium
14. Northwestern University– *Centre for Behavioral Intervention Technologies*, USA
15. Universität Passau – *Complex and Intelligent Systems,* Germany
16. Università degli Studi di Bergamo– *Department of Engineering and Applied Sciences*, Italy
17. Charité – Universitätsmedizin Berlin – *Clinic for Neurology and Clinical Neurophysiology*, Germany
18. Intel Corporation Ltd – Intel Life Sciences and Analytics, UK
19. Janssen Pharmaceutica NV (JPNV)– *Research & Development*, Belgium
20. Biogen Idec Limited – *Value Based Medicine & Clinical Development,* UK
21. H. Lundbeck A/S – *Data Handling R&D & Global Clinical Research*, Denmark
22. UCB Biopharma SPRL – *Innovative Solutions & Assessment,* Belgium
23. MSD IT Global Innovation Center–*Research to Release,* Czech Republik

[Press release]

http://www.radar-cns.org